CoChat

Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat

Freret, Thomas, Valable, Samuel, Chazalviel, Laurent, Saulnier, Romaric, Mackenzie, Eric T., Petit, Edwige, Bernaudin, Myriam, Boulouard, Michel, Schumann‐Bard, Pascale · 2006 · European Journal of Neuroscience
Cited by 125

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The mechanisms underlying functional recovery after stroke are poorly understood. Brain‐adaptive responses to the hypoxic stress elicited by ischemia could contribute to these mechanisms. Indeed, hypoxia‐inducible factor‐1 (HIF‐1), one of the main transcriptional factors regulated by oxygen level, increases the expression of several beneficial genes such as erythropoietin, glucose transporter‐1 and vascular endothelial growth factor. In order to strengthen the expression of these hypoxia‐inducible factors, we administered deferoxamine, an iron chelator known to stabilize HIF‐1α protein expression, and examined its effects on the functional deficits induced by ischemia. Anesthetized Sprague–Dawley rats were subjected to 60 min of intraluminal occlusion of the middle cerebral artery. Chronic deferoxamine treatment (300 mg/kg, s.c.), or its vehicle, started 24 h after ischemia and was continued bi‐weekly until the animals were killed. Sensorimotor deficits were periodically assessed over 2 months, and at this end point, the lesion volume was determined by histology. Treatment with deferoxamine significantly decreased the size of brain damage (−28%) after ischemia and improved behavioral recovery. Indeed, neurological score and sensorimotor performances in the adhesive removal test recovered earlier in the deferoxamine‐treated animals. Moreover, the long‐lasting skilled forepaw reaching deficits were attenuated by deferoxamine. Although an antioxidant effect of deferoxamine cannot be excluded, the hypothesis that its beneficial effects could be mediated by an increase in HIF‐1 target genes merits further investigations. Our data suggest that delayed administration of deferoxamine could represent an interesting therapeutical approach to treat focal cerebral ischemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1460-9568.2006.04699.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 125

Metadata

Authors
Freret, T., Valable, S., Chazalviel, L., Saulnier, R., Mackenzie, E. T., Petit, E., Bernaudin, M., Boulouard, M., & Schumann‐Bard, P.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2006-04
Volume
23
Issue
7
Pages
1757-1765
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W1823048099
Cited by
125
References
4
FWCI
7.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.